Human Microbiome-based Products Market is projected to be worth USD 4 Billion by 2030

Over the years, extensive R&D efforts have enabled microbiome-based therapy / diagnostic developers to make significant strides, in terms of progressing proprietary product candidates into the clinic

Advertisements

 

Roots Analysis has announced the addition of “Human Microbiome Market, 2019-2030” report to its list of offerings

 

The report features an in-depth analysis, highlighting the diverse capabilities of stakeholders engaged in this domain. In addition to other elements, the study includes:

  • A detailed assessment of the current market landscape of microbiome therapeutics, providing information on drug / therapy developer(s).
  • Elaborate profiles of key players (established after 2005) that are engaged in the development of microbiome therapeutics.
  • A detailed review of the current market landscape of microbiome diagnostic tests, brief profiles of popular diagnostic developers and indicative list of screening and profiling test kits.
  • A detailed assessment of the current market landscape of FMT therapies, a geographical clinical trial analysis and information on various stool banks.
  • A detailed business portfolio analysis based on an attractiveness and competitiveness (AC) framework.
  • An analysis of the varied microbiome-focused initiatives of big pharma players.
  • An analysis of the start-ups / small-sized players engaged in the development of microbiome therapeutics and diagnostics.
  • An assessment of the most commonly targeted therapeutic indications and details of microbiome-based drugs.
  • An analysis of the investments made at various stages of development in start-ups / small-sized companies.
  • An indicative list of contract manufacturers, in-house manufacturers and CROs that currently claim to have the necessary capabilities.
  • An assessment of the emerging role of big data highlighting efforts focused on the development and implementation of various algorithms / tools to analyze data generated from in the microbiome research.
  • An informative case study on the various other applications of microbiome products, such as agriculture, animal health, plant health, food products
  • A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)

 

To request for sample – https://www.rootsanalysis.com/reports/281/request-sample.html

 

segments:

  • Type of Therapy (Tx)
  • Prescription Drug
  • Prebiotics
  • Probiotics

 

  • Type of Molecule (Tx)
  • Small Molecules
  • Biologics

 

  • Target Indication (Tx+Dx)
  • Acne Vulgaris
  • Atopic Dermatitis
  • Clostridium difficile Infection
  • Colorectal Cancer
  • Crohn’s Disease
  • Diabetes
  • Irritable Bowel Syndrome
  • Lactose Intolerance
  • Lung Cancer
  • Nonalcoholic steatohepatitis (NASH)
  • Obesity
  • Ulcerative colitis

 

  • Therapeutic Area (Tx+Dx)
  • Autoimmune Disorders
  • Dental Disorders
  • Digestive and Gastrointestinal Disorders
  • Dermatological Disorders
  • Infectious Disease
  • Metabolic Disorders
  • Oncology
  • Others

 

  • Key Geographical Regions (Tx+Dx)
  • North America
  • Europe
  • Asia-Pacific and Rest of the World

 

Key companies covered in the report

  • 4D Pharma
  • Armata Pharmaceuticals
  • Evelo Biosciences
  • Rebiotix (Acquired by Ferring Pharmaceuticals)
  • Seres Therapeutics
  • Vedanta Biosciences